Managing the Cost of Compliance in Pharmaceutical Operations 1
|
|
- Barry Lewis
- 8 years ago
- Views:
Transcription
1 Frances Bruttin and Dr. Doug Dean IBM Business Consulting Services Pharmaceutical Sector Aeschenplatz 2 CH-4002 Basel Switzerland (tel) (fax) Managing the Cost of Compliance in Pharmaceutical Operations 1 Introduction Recent studies have shown that the total cost of compliance with internal quality systems and external regulations for a typical medium to large dosage form manufacturing facility is as high as 25% of the total site operating budget (exclusive of raw material costs) [1]. For a medium-large production facility this amounts to 40 million per year. There is potential to reduce this element of cost by as much as 50%, but not by continuing with the current cause no problems attitude to manufacturing. To reduce compliance costs, it is both necessary to understand the cost components in some detail, and to appreciate why they occur. It is also necessary to balance compliance costs against the incremental reduction to business risk that they deliver. By understanding the nature of compliance-related risk, where it occurs, and how to manage it, significant improvement opportunities may be identified that systematically reduce gross risk and reduce the cost of managing residual risk. Market realities in the 21 st Century require manufacturing operations to be externally supportive and to contribute directly to the competitive advantage of the pharmaceutical enterprise. A significant contribution to improvement of operational cost structures can be realised through a programme focused on reduction of operational compliance costs. This paper will explore how both quality and regulatory compliance costs can be identified and quantified. The risks eliminated by undertaking quality and compliance activities will be analysed in a similar manner. Finally, it will be shown that the risk cost trade-off can become an objective decision-making process contingent on the company s product portfolio and its preferred risk profile. The Pharmaceutical Context Manufacturing has been traditionally regarded as a Cinderella function in the R&Dbased pharmaceutical sector, and has been managed with an internally neutral cause 1 This article originally appeared as A Risk-Based Approach to Dramatic Cost of Compliance Reductions in Pharmaceutical Manufacturing,Pharmaceutical Technology Europe, vol. 11, no. 5, pp April 2004 Page 1 of 9
2 no problems mentality. This attitude has resulted in the growth of inefficiencies in several areas, resulting in today s unacceptably high costs of compliance. With dosage form facilities spending 20-25% of annual operating budgets to ensure that no compliance-related problems occur, this is an expensive insurance policy. With such an expensive policy premium, it could be assumed that senior management has clear visibility of the component costs and is able to state, based on objective criteria, whether the company is over or under insured. One would also assume that management should be in a position to state with confidence if incremental investment in their compliance infrastructure to reduce risk still further made economic sense. Evidence from the industry, however, indicates that this is seldom the case. Despite the significant spend on compliance the more frequently encountered situation is instead one where business people searching for operational cost reductions are informed by q.c. unit professionals that higher, not lower, levels of compliance are required with associated increases, not decreases, in costs. This often creates a sense of management dissatisfaction given the feeling that costs are high; interpretation of GMP regulations is a black art; and the level of compliance problems seems to remain constant anyhow, independent of the level of compliance-related spend. The Status Quo It is our opinion that this discussion is frequently played out because: Most pharmaceutical companies do not know what their total cost of compliance is, or what cost components contribute significantly to the total; Most pharmaceutical companies do not really understand what level of compliance they are attaining, or failing to attain, with existing infrastructures; Few pharmaceutical companies have visibility of the residual risks to which they are exposed at the given level of compliance with which they operate; Few pharmaceutical companies understand the capability of their compliance infrastructure to deliver marginal reductions in compliance risk; Few pharmaceutical companies understand the relationship between their level of compliance risk exposure and the associated costs. The Problem As a consequence, management often has great difficulty objectively answering two critical questions: Is more investment in infrastructure warranted to reduce existing compliancerelated risk exposure? Does the level of compliance currently being delivered by the infrastructure represent good value given the cost required to achieve this level? April 2004 Page 2 of 9
3 These issues of excessive compliance costs and ineffective compliance infrastructures have been a topic of discussion in the industry for some time [2-4]. In our experience, an integrated risk management approach to these questions of quality and regulatory compliance is necessary to enable senior business management gain visibility of compliance costs, and to manage them effectively. Integrated Risk Management Risk management is fundamentally concerned with: Identifying gross risk Quantifying gross risk Deciding what to do about unacceptable risk Implementing the decisions to modify risk Managing the residual acceptable risk Integrated risk management examines risk across functions and disciplines with the knowledge that risk exposure may not always occur at the organisational location of risk generation. Risk reduction efforts may lead to a zero sum improvement if efforts are not consolidated and co-ordinated in this manner. Applying a systematic and integrated framework to regulatory risk enables affiliate, regional, and global manufacturing managers to objectively assess their unit s compliance exposure and communicate the performance of the risk controls in place to mitigate that exposure. The Approach to Regulatory Risk Management Regulatory risk within pharmaceutical manufacturing is primarily concerned with cgmp compliance. This involves product fitness for use and compliance with regulatory controls. Product fitness for use is an attribute that most companies, irrespective of industry, need to assure. Although product fitness for use comprises more than product quality (safety and efficacy as well), we will identify this category of cost and risk as Quality. Compliance with regulatory controls, however, may be regarded as the incremental effort needed to satisfy the requirements of regulatory agencies. This is the incremental cost of doing business in strongly regulated industries such as health care product manufacturing and the aerospace sector. We shall identify this category of cost and risk as Regulatory Control. Compliance Risk = Quality Risk + Regulatory Control Risk Figure 1. The components of Compliance Risk April 2004 Page 3 of 9
4 Risk Identification The first step of risk identification requires profiling the state of the Quality and Regulatory Control infrastructures as potential generators of compliance risk. Some examples of problem areas and potential risk generators are shown in Table 1. Quality Raw materials Equipment Personnel Processes and others Regulatory Control GMP documentation system Master instructions Computer-related systems Validation and others Table 1. Examples of potential risk generators Risk Quantification Risk quantification involves establishing the current levels of Quality and Regulatory Control compliance in terms of process inputs, processes, process outputs, and operational practices. A number of methods, some of which have only recently been developed, exist to measure these levels: Process capability indexing, and sigma profiling [5]; Regulatory compliance risk indexing [6]; Performance benchmarking against best practice maturity profiles. Using the above quantification methods, managers gain insight into the current risk exposure of their Quality and Regulatory Controls compliance infrastructure. Visibility must be established of the cost to attain the current level of compliance, and where those costs occur. One must also understand the potential risk reduction resulting from an incremental investment in the compliance infrastructure. Identification of Poor Quality Costs Poor quality costs may be classified into four categories: Internal Failure Costs: Costs associated with defects found prior to the transfer of finished goods to the customer. External Failure Costs: Costs associated with defects found after shipment of finished goods to the customer. Appraisal Costs: Costs incurred in determining the degree of conformance to quality requirements before shipment of finished goods to the customer. Prevention Costs: Costs incurred in seeking to minimise failure and appraisal costs before and after shipment of finished goods to the customer. April 2004 Page 4 of 9
5 A detailed examination of these cost categories is beyond the scope of this paper, but some category examples are listed in Table 2. Internal Failure External Failure Appraisal Prevention Safety Stock Distribution Service errors Incoming material evaluation Quality System Maintenance Destruction Costs Product Insurance Inspections Process Control Over Fill Costs Litigation expenses Evaluation of stock QA Audits Material Yield Costs Judgements Calibration Services Supplier Quality evaluation Efficiency Loss Downtime Complaint Investigation Downgrading Defective Product Replacement Table 2. Examples of the categories of poor quality cost Product Inspection Training Preventative Equipment Maintenance Identification of Regulatory Control Non-Compliance Costs Non-Compliance costs may be categorised in a manner similar to poor quality costs. These costs are related to the control element of compliance alignment of process, product and regulatory documentation [7]. Internal Failure Costs: Costs associated with control document errors found prior to finished goods release. External Failure Costs: Costs associated with report document errors found after shipment of finished goods to the customer. Appraisal Costs: Costs incurred in determining the degree of conformance to Regulatory Control requirements before shipment of finished goods to the customer. Prevention Costs: Costs incurred in keeping failure and appraisal costs to a minimum before and after shipment of finished goods to the customer. Again, detailed examination of all possible categories of non-compliance costs is beyond the scope of this paper. Table 3 illustrates some examples of categories of these cost elements. April 2004 Page 5 of 9
6 Internal Failure External Failure Appraisal Prevention Re-processing semifinished goods due to batch record errors and omissions Recall processing Document review & approval Supplier Certification Scrap due to batch record errors and omissions Citation and Warning letter processing QC release certificate processing Deviation Processing NDA delay Batch Record processing Change Control Batch record rework Investigation Reports Shareholder Value Business Income Reputation Complaint Processing Validation SOP development & maintenance Table 3. Examples of non-compliance cost categories Quantifying Costs Considering that costs are generated due to the consumption of either time or materials, it makes sense to categorise further the costs under headings of Activity and Material. Consolidating in this manner produces a Compliance Cost Matrix as illustrated in Table 4. System Compliance Quality Regulatory Control Activity Material Activity Material Internal Failure Downtime Complaint investigation Rework External Failure Compliant investigation Prevention Quality System Maintenance QA Audits Training Appraisal Inspections Incoming material evaluation Calibration services Evaluation of stock Table 4. Compliance cost matrix. Overfill Material yield Downgrading Scrap Defect product replacement Product insurance Litigation Rework (BR errors) Deviation processing Change Control BR rework Recall processing Citation & warning letter processing Validation SOP development & maintenance Master Batch record development Document review and approval QC release certificate processing Batch record processing Scrap (BR errors) NDA delay Shareholder value Reputation Business income April 2004 Page 6 of 9
7 Using techniques such as Activity Based Costing (ABC) and Material Failure Cost Analysis, it is possible to populate the Compliance Cost Matrix in a manner which promotes transparency and inter-departmental responsibility. A detailed and complete discussion of ABC is outside the scope of this paper. Briefly, however, the technique assesses costs based on completion of an inventory of activities performed by each employee in a given time period. Further, each activity has a result, or output, and may consume additional resources that are also identified. Using ABC techniques, one can be certain of creating a comprehensive and very revealing map of costs. ABC cost maps tend to be much more indicative of where actual costs are being accrued. They provide a level of detail that is missing in a traditional roll-up of departmentally allocated costs. For example it becomes obvious that quality costs occur not only in the quality department, but also in production (rework) and customer relations (compliant investigation). Another advantage of such a matrix is that it highlights sources of potentially large financial risk related to Regulatory Control non-compliance for example loss of shareholder value and reputation. With a clear view of the cost structure, executives are now in a position to determine the performance level of Quality and Regulatory Control compliance infrastructures, and decide if they are under or over-exposed to regulatory risk. Performance Level Following Juran [8] it is possible to develop a total compliance curve summing the costs of appraisal and prevention with failure costs. Total compliance costs Cost of Compliance Cost of Appraisal & Prevention Failure costs Level of Compliance Figure 2. Total cost of compliance as a function of compliance level. Optimising the level of compliance in correspondence with the economic minimum is generally not a concept acceptable in the pharmaceutical industry. Companies need to know what their compliance cost curve actually is, and where on it they are currently operating, so as to their current compliance and quality gross risk exposure. Deciding what to do about that gross risk depends on the company s preferred risk profile, its capital structure, its future trading paradigm and its product portfolio. Some companies are risk seeking and are prepared to accept a level of risk higher that the industry average. Privately held companies may not be worried about shareholder value. Companies considering significant contract manufacturing in the future may April 2004 Page 7 of 9
8 need to greatly reduce their gross risk. Factors such as dosage forms, technology and complexity of processes, influence where a company can sensibly operate on its' compliance curve. Whatever the assumptions and limitations involved, senior management, knowing with clarity their operating position, are now able to compare options which will allow them to eliminate, transfer, or modify, gross compliance risk. Implementing the options will additionally allow containment of the cost of managing the residual compliance risks. Reducing Gross Risk and Improving Compliance Effectiveness Best-in-class companies that have systematically reduced their compliance risk, have noticed that, surprisingly, as the level of compliance improved, the cost of compliance actually decreased. Although it is completely counter intuitive given the current mentality and track record of quality and compliance professionals in the pharma sector, this phenomenon that has been observed in other industries Cost Cost Saving 40-50% X 0 0% 40% 50% 60% 70% Degree of Compliance 90% 100% 100% 10% 20% 30% 80% Figure 3. Reducing the cost of compliance This approach has been shown to allow recovery of 40-50% of existing compliance costs. Alternatively, operation at significantly increased levels of compliance with concomitant reduction in risk is also an option to executive management. Compliance cost and risk reduction methods are individually effective, and each is certainly of stand-alone benefit. However, such methods combined to form an overall program they can move the compliance capabilities of manufacturing from being at best internally neutral, to becoming externally supportive, and hence a source of competitive advantage. Conclusions An integrated risk management approach to management of compliance within the pharmaceutical sector should look at Quality and Regulatory Controls in terms of April 2004 Page 8 of 9
9 their compliance infrastructures. Identifying and quantifying the level and cost of these infrastructures makes the sources and consequences of regulatory risk visible. Obtaining transparency of the aggregate compliance level and associated costs allows management to make knowledge-based, rather than subjective, decisions on the optimal degree of compliance. The steps taken to modify the cost-risk profile will be contingent on a company s target risk profile and product portfolio. Innovative methods to reduce gross risk have led to a fundamental change in the compliance curve enabling leading companies to benefit from cost savings of 40-50%. A focused program to reduce gross risk and contain the cost of managing residual risk may move manufacturing from being internally neutral, to being externally supportive, thereby contributing to competitive advantage. References 1. Dean, D., and Bruttin, F., Profiling Costs in the Hidden Factory of Pharmaceutical Production, PricewaterhouseCoopers, Pharma Sector Study and Report, Uxbridge, UK, Anisfeld, M.H., Validation How Much Can the World Afford? Are We Getting Value for Money?, PDA Journal of Pharmaceutical Science & Technology, Vol. 48, No. 1, pp , Jan.- Feb Bruttin, F., and Dean, D., Exposing a Cost Black Hole While Improving Quality and Compliance Through Integrated Risk Management, Proceedings, WorldPharm98, Philadelphia, USA, September, Kieffer, R.G., Global Trends, Needs, Issues, PDA Journal of Pharmaceutical Science & Technology, Vol. 52, No. 4, pp , Jul.-Aug Dean, D., Bruttin, F., and McCracken, P., Applying Best Practices in Production of Large and Small Volume Parenterals to Achieve a 2:1 Cost and Performance Advantage, Proceedings, PDA 1998 International Congress - Advances in Pharmaceutical Manufacturing, pp , Basel, February, Chapman, K.G., Bruttin, F., and Dean, D., Gaining Management Visibility of Potential Compliance Risks by Regulatory Compliance Indexing, PricewaterhouseCoopers, Pharma Sector Study and Report, Uxbridge, UK, Tetzlaf, R.F., GMP Documentation Requirements for Automated Systems: Parts I, II, and III, Pharmaceutical Technology, Vol. 16, No. 3, pp , 1992, Vol. 16, No. 4, pp , 1992, Vol. 16, No. 5, pp , Juran, J.M, and Gryna, F., Quality Planning and Analysis, 3 rd edition, McGraw-Hill, New York, 1993, pp April 2004 Page 9 of 9
ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 038-1 26 March 2012 AIDE-MEMOIRE ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PIC/S March 2012 Reproduction
More informationThe Asset Management Landscape
The Asset Management Landscape ISBN 978-0-9871799-1-3 Issued November 2011 www.gfmam.org The Asset Management Landscape www.gfmam.org ISBN 978-0-9871799-1-3 Published November 2011 This version replaces
More informationAligning Quality Management Processes to Compliance Goals
Aligning Quality Management Processes to Compliance Goals MetricStream.com Smart Consulting Group Joint Webinar February 23 rd 2012 Nigel J. Smart, Ph.D. Smart Consulting Group 20 E. Market Street West
More informationProductivity and the Economics of Regulatory Compliance in Pharmaceutical Production
Productivity and the Economics of Regulatory Compliance in Pharmaceutical Production Doug Dean & Frances Bruttin PwC Consulting Pharmaceutical Sector Team Basel, Switzerland Declaring a Few Biases...!Business!Manufacturing!Systems!Big
More informationThe FDA recently announced a significant
This article illustrates the risk analysis guidance discussed in GAMP 4. 5 By applying GAMP s risk analysis method to three generic classes of software systems, this article acts as both an introduction
More informationICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
More informationRecognised Investment Exchanges. Chapter 2. Recognition requirements
Recognised Investment Exchanges Chapter Recognition REC : Recognition Section.3 : Financial resources.3 Financial resources.3.1 UK Schedule to the Recognition Requirements Regulations, Paragraph 1 (1)
More informationA Risk Management Standard
A Risk Management Standard Introduction This Risk Management Standard is the result of work by a team drawn from the major risk management organisations in the UK, including the Institute of Risk management
More informationRegulatory Expectations of Executive Management
Regulatory Expectations of Executive Management Steven Lynn, MS, CMQ/OE Director Office of Manufacturing and Product Quality Office of Compliance CDER/US FDA PDA ICH Q10 Executive Management Workshop PDA
More informationGUIDANCE NOTE FOR DEPOSIT-TAKERS. Operational Risk Management. March 2012
GUIDANCE NOTE FOR DEPOSIT-TAKERS Operational Risk Management March 2012 Version 1.0 Contents Page No 1 Introduction 2 2 Overview 3 Operational risk - fundamental principles and governance 3 Fundamental
More informationFinal Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed by the ICH SC on 10 November 2005
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Final Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed
More informationTHE INSURANCE BUSINESS (SOLVENCY) RULES 2015
THE INSURANCE BUSINESS (SOLVENCY) RULES 2015 Table of Contents Part 1 Introduction... 2 Part 2 Capital Adequacy... 4 Part 3 MCR... 7 Part 4 PCR... 10 Part 5 - Internal Model... 23 Part 6 Valuation... 34
More informationUnderstanding and articulating risk appetite
Understanding and articulating risk appetite advisory Understanding and articulating risk appetite Understanding and articulating risk appetite When risk appetite is properly understood and clearly defined,
More informationOne year to go How fit are Swiss companies?*
Internal Control Systems One year to go How fit are Swiss companies?* Survey (November 2007) Contents Introduction 3 Executive summary 4 How do risk assessment and scoping interlink? 6 How are internal
More informationPerformance Measurement
Performance Measurement Introduction Performance measurement is a fundamental building block of TQM and a tal quality organisation. Hisrically, organisations have always measured performance in some way
More informationA7/SA report/nov10 1
A7/SA report/nov10 1 INFORMATION FOR CANDIDATES The senior assessor s report is written in order to provide candidates with feedback relating to the examination. It is designed as a tool for candidates
More informationBridgend County Borough Council. Corporate Risk Management Policy
Bridgend County Borough Council Corporate Risk Management Policy December 2014 Index Section Page No Introduction 3 Definition of risk 3 Aims and objectives 4 Strategy 4 Accountabilities and roles 5 Risk
More informationQuality Thinking in other Industries. Dominic Parry Inspired Pharma Training. WEB www.inspiredpharma.com GMP BLOG inspiredpharmablog.
Quality Thinking in other Industries Dominic Parry Inspired Pharma Training WEB www.inspiredpharma.com GMP BLOG inspiredpharmablog.com Welcome The traditional focus on quality Quality in the eyes of GMP
More informationQuality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation
Quality Assurance Disclosure for Lilli Møller Andersen No relevant financial relationships exist for any issue mentioned in this presentation Agenda Quality Assurance Quality Management System Quality
More informationInternal Audit Quality Assessment Framework
Internal Audit Quality Assessment Framework May 2013 Internal Audit Quality Assessment Framework May 2013 Crown copyright 2013 You may re-use this information (excluding logos) free of charge in any format
More informationChapter 1 Developing a healthy appetite for risk [DTI] 3. Chapter 2 Getting the best bang per buck [DEFRA] 5
CONTENTS Page Chapter 1 Developing a healthy appetite for risk [DTI] 3 Chapter 2 Getting the best bang per buck [DEFRA] 5 Chapter 3 Getting your house in order [Companies House] 9 Thinking About Risk -
More informationConfident in our Future, Risk Management Policy Statement and Strategy
Confident in our Future, Risk Management Policy Statement and Strategy Risk Management Policy Statement Introduction Risk management aims to maximise opportunities and minimise exposure to ensure the residents
More informationMoving from Quality Control to Quality Assurance (Proactive Compliance!)
Moving from Quality Control to Quality Assurance (Proactive Compliance!) Guy Wingate, VP & Compliance Officer Global Manufacturing & Supply, GlaxoSmithKline Disclaimer The views and opinions expressed
More information1. Scope This SOP covers requirements for PHARMCO-AAPER s Quality Management System
Page 1 of 8 1. Scope This SOP covers requirements for PHARMCO-AAPER s Quality Management System 2. Application This Standard Operating Procedure applied to the entire Quality Management System as it relevant
More informationQuality and Quality Control
1 Quality and Quality Control INSPECTION Inspection is the most common method of attaining standardisation, uniformity and quality of workmanship. It is the cost art of controlling the product quality
More informationBiopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities
1 Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities Presented by Dr. Philipp Hess Supply Chain Management Issues and Opportunities 2 1. How do we
More informationApplication of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations
Application of Quality Risk Management to Pharmaceutical Operations Eldon Henson, Vice President, Quality Operations Key Topics of Discussion Definition of Quality Risk Management (QRM) Overview of PDA
More informationCapital Adequacy: Advanced Measurement Approaches to Operational Risk
Prudential Standard APS 115 Capital Adequacy: Advanced Measurement Approaches to Operational Risk Objective and key requirements of this Prudential Standard This Prudential Standard sets out the requirements
More informationEffective Asset Management for Life Sciences
Effective Asset Management for Life Sciences The business value Life sciences companies face stiff challenges to their long-term profitability in the form of mounting regulatory pressures, increasing price
More informationSunora Foods Inc. Condensed Interim Consolidated Financial Statements For the three months ended March 31, 2016 (unaudited)
Condensed Interim Consolidated Financial Statements For the three months ended March 31, 2016 (unaudited) 1 Consolidated Balance Sheet (audited) March 31, December 31, Assets 2016 2015 Current assets Cash
More informationQuality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
More informationICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010 Joseph C. Famulare Head of External Relations and Collaboration Pharma Global Technical Operations Global Quality, F. Hoffmann-La
More informationUsing the Cost of Poor Quality to Drive Process Improvement
Using the Cost of Poor Quality to Drive Process Improvement March, 2006 Presented by: Dan Olivier, Certified Software Solutions, Inc. (dolivier@certifiedsoftware.com) Javad Seyedzadeh, Bayer Healthcare
More informationMastering working capital to build financially sustainable supply chains: A research perspective
Mastering working capital to build financially sustainable supply chains: A research perspective Simon Templar I would like to acknowledge the assistance of the International Supply Chain Finance Community
More informationManagement Accounting 2 nd Year Examination
Management Accounting 2 nd Year Examination August 2012 Exam Paper, Solutions & Examiner s Report NOTES TO USERS ABOUT THESE SOLUTIONS The solutions in this document are published by Accounting Technicians
More informationMHRA GMP Data Integrity Definitions and Guidance for Industry March 2015
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
More informationWORKING CAPITAL MANAGEMENT
CHAPTER 9 WORKING CAPITAL MANAGEMENT Working capital is the long term fund required to run the day to day operations of the business. The company starts with cash. It buys raw materials, employs staff
More informationUsing Training Data to Drive Up Quality Metrics SURVEY OF QUALITY ASSURANCE EXECUTIVES
Using Training Data to Drive Up Quality Metrics SURVEY OF QUALITY ASSURANCE EXECUTIVES SURVEY OF QUALITY ASSURANCE EXECUTIVES The FDA s Push for Data and Metrics For the US FDA investigator, the single
More informationQuality Cost Analysis: Benefits and Risks
Quality Cost Analysis: Benefits and Risks Copyright Cem Kaner January, 1996 All rights reserved Because the main language of [corporate management] was money, there emerged the concept of studying quality-related
More informationBenchmark of controls over IT activities. 2011 Report. ABC Ltd
www.pwc.com/cy Benchmark of controls over IT activities 2011 Report ABC Ltd... 2012 Scope and approach We wish to provide you with our IT Benchmarking report over IT activities at ABC Ltd (the Company)
More informationExample Summary of how to calculate Six Sigma Savings:
Example Summary of how to calculate Six Sigma Savings: Six Sigma calculations are based on current period actual activity vs. prior period actual activity. Reported Six Sigma Direct Savings must therefore
More informationRegulations in General Insurance. Solvency II
Regulations in General Insurance Solvency II Solvency II What is it? Solvency II is a new risk-based regulatory requirement for insurance, reinsurance and bancassurance (insurance) organisations that operate
More informationImproved Utilization of Self-Inspection Programs within the GMP Environment A Quality Risk Management Approach
Improved Utilization of Self-Inspection Programs within the GMP Environment A Quality Risk Management Approach Barbara Jeroncic Self-inspection is a well-established and vital part of the pharmaceutical
More informationOptimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy
Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting
More informationProduct Lifecycle Management in the Medical Device Industry. An Oracle White Paper Updated January 2008
Product Lifecycle Management in the Medical Device Industry An Oracle White Paper Updated January 2008 Product Lifecycle Management in the Medical Device Industry PLM technology ensures FDA compliance
More informationShepway District Council Risk Management Policy
Shepway District Council Risk Management Policy Contents Section 1 Risk Management Policy... 3 1. Updates and amendments... 3 2. Definition... 3 3. Policy statement... 3 4. Objectives... 3 Section 2 Risk
More informationTopic 12 Total Quality Management. From Control to Management. Deming s Fourteen Points for TQM
Topic 12 Total Quality Management From Control to Management 1 Inspection Error detection of finished goods Rectification Reading guide: Chapter 20 (Slack et al, 2004) and MGT326 Slides/Handout 1 2 Quality
More informationVDA6.3 Process Audit Webinar 1 st April 2014. Paul Hardiman Qualified VDA6.3 trainer
VDA6.3 Process Audit Webinar 1 st April 2014 Paul Hardiman Qualified VDA6.3 trainer During presentations (11:00 11:30) everyone will be muted so that only the presenter will be heard. The presentation
More informationPrinciples and Trade-Offs when Making Issuance Choices in the UK
Please cite this paper as: OECD (2011), Principles and Trade-Offs when Making Issuance Choices in the UK, OECD Working Papers on Sovereign Borrowing and Public Debt Management, No. 2, OECD Publishing.
More informationOperational Business Intelligence in Manufacturing
Operational Business Intelligence in Manufacturing Copyright 2007 KeyTone Technologies Inc. Page 1 SmartWIP - Intelligent Manufacturing with RFID Manufacturers are under competitive pressure to fulfill
More information1 The quality management system (QMS) is the corner stone of compliance to GMP. The QMS is made up of several documents, that when followed ensures the GMP compliance of the process, facility and company.
More informationINTERNAL AUDIT CHARTER AND TERMS OF REFERENCE
INTERNAL AUDIT CHARTER AND TERMS OF REFERENCE CHARTERED INSTITUTE OF INTERNAL AUDIT DEFINITION OF INTERNAL AUDIT Internal auditing is an independent, objective assurance and consulting activity designed
More informationV1.0 - Eurojuris ISO 9001:2008 Certified
Risk Management Manual V1.0 - Eurojuris ISO 9001:2008 Certified Section Page No 1 An Introduction to Risk Management 1-2 2 The Framework of Risk Management 3-6 3 Identification of Risks 7-8 4 Evaluation
More informationIT Governance. What is it and how to audit it. 21 April 2009
What is it and how to audit it 21 April 2009 Agenda Can you define What are the key objectives of How should be structured Roles and responsibilities Key challenges and barriers Auditing Scope Test procedures
More informationQSS 0: Products and Services without Bespoke Contracts.
QSS 0: Products and Services without Bespoke Contracts. Amendment History Version Date Status v.1 Dec 2014 Updated For 2015 deployment Table of Contents 1. DEFINITIONS 3 2. INTRODUCTION 3 3. WORKING WITH
More informationExecutive summary... 3 Overview of S&OP and financial planning processes... 4 An in-depth discussion... 5
Table of contents Executive summary... 3 Overview of S&OP and financial planning processes... 4 An in-depth discussion... 5 What are the benefits of S&OP and financial planning integration?... 5 Why is
More informationAssessing the Cost of Poor Quality
Assessing the Cost of Poor Quality Convincing OEMs to invest in preventive actions may be as simple as showing them the numbers. The key is to understand the costs associated with a poor quality system.
More informationTotal Quality Management and Cost of Quality
Total Quality Management and Cost of Quality Evsevios Hadjicostas The International Quality movement Operator Quality Control Foreman (Supervisor) Quality Control Full-time Inspectors Statistical Quality
More informationCloud aggregation from Computacenter
Cloud aggregation from Computacenter IT S FAST. IT S FLEXIBLE. IT S FLUID. IT S THE FUTURE. The promise of greater agility, efficiency and cost control has cemented cloud computing in the corporate IT
More informationCOMPARATIVE STUDY BETWEEN TRADITIONAL AND ENTERPRISE RISK MANAGEMENT A THEORETICAL APPROACH
COMPARATIVE STUDY BETWEEN TRADITIONAL AND ENTERPRISE RISK MANAGEMENT A THEORETICAL APPROACH Cican Simona-Iulia Management, Faculty of Economics and Business Administration, West University of Timisoara,
More informationAsset Factory is a software service that allows you to manage the value, costs, risks and performance of your property, people and supply chain
Asset Factory is a software service that allows you to manage the value, costs, risks and performance of your property, people and supply chain assets. It is simple to use and provides instant reporting
More informationQuality Metrics An FDA Perspective PDA Dinner and Dialogue. Melissa Seymour VP, Corporate Quality DRAFT
Quality Metrics An FDA Perspective PDA Dinner and Dialogue Melissa Seymour VP, Corporate Quality DRAFT Agenda How does industry use Metrics? FDA Challenges and Requirements and Use Complexities of Implementation
More informationGUIDELINES ON CORPORATE GOVERNANCE FOR LABUAN BANKS
GUIDELINES ON CORPORATE GOVERNANCE FOR LABUAN BANKS 1.0 Introduction 1.1 Good corporate governance practice improves safety and soundness through effective risk management and creates the ability to execute
More informationCOST AND MANAGEMENT ACCOUNTING
EXECUTIVE PROGRAMME COST AND MANAGEMENT ACCOUNTING SAMPLE TEST PAPER (This test paper is for practice and self study only and not to be sent to the institute) Time allowed: 3 hours Maximum marks : 100
More informationEmptoris Contract Management Solution for Healthcare Providers
Emptoris Contract Management Solution for Healthcare Providers An Emptoris White Paper Emptoris, an IBM Company www.emptoris.com CMS-HP-4/12 Emptoris Contract Management Solution for Healthcare Providers
More informationUnit 6: INTRODUCTION TO QUALITY ASSURANCE and TOTAL QUALITY MANAGEMENT (key-words: pre-fabrication, site assembly, integrated systems)
1 Unit 6: INTRODUCTION TO QUALITY ASSURANCE and TOTAL QUALITY MANAGEMENT (key-words: pre-fabrication, site assembly, integrated systems) INTRODUCTION TO QUALITY ASSURANCE and TOTAL QUALITY MANAGEMENT QUALITY
More informationAdvisory Guidelines of the Financial Supervisory Authority. Requirements regarding the arrangement of operational risk management
Advisory Guidelines of the Financial Supervisory Authority Requirements regarding the arrangement of operational risk management These Advisory Guidelines have established by resolution no. 63 of the Management
More informationA 10-Minute Guide to Increasing Supply Chain Visibility
A 10-Minute Guide to Increasing Supply Chain Visibility 1 CONTENT MAKE THE CASE LEVEL 1 - VIEW THE INVENTORY LEVEL 2 - COLLABORATE SMARTER LEVEL 3 - TRACK & TRACE CONCLUSION 2 MAKE THE CASE It s imperative
More informationAnnex 7 Guidelines on pre-approval inspections
World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the
More informationcc quality management
Business-Software for People Business- Software for People cc quality management user ability to customize quality parameters management of different test procedures customer and vendor specific test plans
More informationExceptional Customer Experience: The New Supply Chain Management Focus
White Paper Exceptional Customer Experience: The New Supply Chain Management Focus Jonathan Gross Contents A Fresh Look at Supply Chain Management....2 Factors Driving the Integration of Supply Chain Management
More informationMichael Kickuth and Thomas Friedli
IV Operational Excellence in the Pharmaceutical Industry: Case Studies from the Field In this chapter we want to give some guidance for people responsible for implementing Operational Excellence programs.
More informationRISK MANAGEMENT OVERVIEW 2011 RISK CONFERENCE SPONSORED BY THE FEDERAL RESERVE BANK OF CHICAGO AND DEPAUL UNIVERSITY
RISK MANAGEMENT OVERVIEW 2011 RISK CONFERENCE SPONSORED BY THE FEDERAL RESERVE BANK OF CHICAGO AND DEPAUL UNIVERSITY PRESENTED BY: LEN WIATR, CHIEF RISK OFFICER Len s Risk Management Philosophy Build a
More informationIndustry Solutions Process Manufacturing Flexible and Agile Engineering Document Control for Efficient, Safe and Compliant Plants
Industry Solutions Process Manufacturing Flexible and Agile Engineering Document Control for Efficient, Safe and Compliant Plants Industry Solutions Key Challenges Facing Process Manufacturing High energy
More informationProduct Lifecycle Management in the Food and Beverage Industry. An Oracle White Paper Updated February 2008
Product Lifecycle Management in the Food and Beverage Industry An Oracle White Paper Updated February 2008 Product Lifecycle Management in the Food and Beverage Industry EXECUTIVE OVERVIEW Companies in
More informationAccounts Payable Automation: Top 9 Reasons to Automate: The Essential Guide to Why Your Business Needs to Automate its Invoice Processing.
Whitepaper Accounts Payable Automation: Top 9 Reasons to Automate: The Essential Guide to Why Your Business Needs to Automate its Invoice Processing. June 2014 Overview Reducing costs, improving performance,
More informationThe Paperless QMS March 2012
The Paperless QMS March 2012 Overview Introductions What do we mean by Paperless QMS? Short history of the (pharma) Paperless QMS What do you need your Paperless QMS to do? Practical application and considerations
More informationQuestions 1, 3 and 4 gained reasonable average marks, whereas Question 2 was poorly answered, especially parts (b),(c) and (f).
General Comments This sitting produced a reasonable pass rate for a resit paper although there was a large variation in pass rates between centres. It was clear that well-prepared candidates did not have
More informationCommercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations
Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical
More informationTitle:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions
WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing
More informationEnhanced Portfolio Management in uncertain times
Enhanced Portfolio Management in uncertain times How businesses can generate and protect value through enhanced, risk return techniques improving portfolio and capital allocation decisions Contents Executive
More informationBusiness-critical Insurance
Business-critical Insurance Identifying those insurances that support the business and its strategy Guide 2015 Contents Introduction... 4 Categories of insurance... 5 Determining which insurance covers
More informationMHRA GMP Data Integrity Definitions and Guidance for Industry January 2015
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
More informationPlacing a Value on Enterprise Risk Management ADVISORY
Placing a Value on Enterprise Risk Management ADVISORY Placing a Value on Enterprise Risk Management 1 In turbulent economic times, the case for investing in an enterprise risk management (ERM) program
More informationMeet Global Food Safety Standards and Increase Productivity and Profitability
Food Focus Regulatory Compliance News 1 Meet Global Food Safety Standards and Increase Productivity and Profitability Food safety concerns are enough to bring a company to the media s attention. The introduction
More informationRisk-Based Validation of Computer Systems Used In FDA-Regulated Activities
September 2, 2003 Risk-Based Validation of Computer Systems Used In FDA-Regulated Activities Purpose This document provides a summary of the requirements relating to use of computer-based systems in activities
More informationRisk Management Policy
Risk Management Policy Responsible Officer Author Ben Bennett, Business Planning & Resources Director Julian Lewis, Governance Manager Date effective from December 2008 Date last amended December 2012
More informationMCQ: Unit -2: Operation processes
MCQ: Unit -2: Operation processes 1.What type of process would a Cement plant be most likely to use? a. Continuous flow b. Project c c. Job shop d. Flow shop 2. Process selection is primarily considered
More informationPROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal
More informationASSET MANAGEMENT. John Woodhouse. The Woodhouse Partnership Ltd
ASSET MANAGEMENT John Woodhouse The Woodhouse Partnership Ltd 1 What is Asset Management? Another catch-phrase, another management initiative or just re-working of good old common sense? We have certainly
More informationEnergy saving technology to deliver the fastest returns. Top 10 energy saving options
Energy saving technology to deliver the fastest returns Top 10 energy saving options How can you increase efficiency, reduce costs and cut your carbon emissions? Unstable energy prices, increased costs,
More informationHow to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters
environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing
More informationPart B1: Business case developing the business case
Overview Part A: Strategic assessment Part B1: Business case developing the business case Part B2: Business case procurement options Part B3: Business case funding and financing options Part C: Project
More informationDocument and Data Control
Document and Data Control An Integral Component of Quality Management Companies that produce products with rigorous quality requirements face numerous challenges associated with meeting quality objectives
More informationMeeting the challenge of software quality and maximizing return on investment Performance driven. Quality assured.
Testing Services Meeting the challenge of software quality and maximizing return on investment Performance driven. Quality assured. Introduction Today, insightful IT departments understand that software
More informationEVERYTHING YOU NEED TO KNOW ABOUT INVENTORY
EVERYTHING YOU NEED TO KNOW ABOUT INVENTORY Introduction Inventory is considered the necessary evil of the supply chain. In fact, there has been a whole movement; lean manufacturing that has tried to reduce
More informationRISK MANAGEMENT GUIDANCE FOR GOVERNMENT DEPARTMENTS AND OFFICES
RISK MANAGEMENT GUIDANCE FOR GOVERNMENT DEPARTMENTS AND OFFICES GOVERNMENT ACCOUNTING SECTION DEPARTMENT OF FINANCE MARCH 2004 Risk Management Guidance CONTENTS Pages List of guidelines on risk management
More informationExcerpt from the ACGR on Enterprise Risk Management
Excerpt from the ACGR on Enterprise Risk Management F. RISK MANAGEMENT SYSTEM 1) Disclose the following: (a) Overall risk management philosophy of the company; Objectives and Policies The Group has significant
More informationRecent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
More informationAsset Management Policy March 2014
Asset Management Policy March 2014 In February 2011, we published our current Asset Management Policy. This is the first update incorporating further developments in our thinking on capacity planning and
More information